SUMMARY Left ventricular function and exercise capacity were assessed in 79 patients randomised to receive intravenous and oral propranolol (n = 44) or conventional therapy (n = 35) within four hours of onset of their first myocardial infarction. Cineangiocardiography 
Infarct size, reflected by the degree of left ventricular dysfunction, is accepted as the major predictor of cardiac mortality after myocardial infarction. Limitation of infarct size with propranolol was first shown experimentally by Maroko and colleagues in 19711 and indirect indices of infarct size have been used in man to demonstrate a beneficial effect of beta blockers.2-4 The hypothesis, however, that limitation of infarct size would lead to improvement in ventricular function has been poorly evaluated in man. Pathophysiological observations suggest that treatment would be most effective if it were started earlywithin four hours of the onset of infarction. 5 We have analysed late ventricular function and exercise capacity in a group of patients randoniised to receive intravenous propranolol or conventional therapy within four hours of onset of their first infarction. Accepted for publication 10 June 1985 vention was conducted in 735 patients with suspected myocardial infarction.6 Entry to the trial was required within four hours of the onset of chest pain, which was of at least 30 minutes' duration and judged to be due to myocardial ischaemia. Exclusion criteria were asthma, significant cardiac failure, systolic blood pressure below 110 mm Hg, or heart rate below 60 beats per minute. Intravenous propranolol (0 1 mg/kg) was followed by an oral dose of up to 320 mg given over the next 27 
Study group
Of the 735 patients admitted to the randomised trial, 407 developed myocardial infarction. Of these, 94 patients were enrolled at one hospital and met our inclusion criteria for subsequent investigation of sex (male), age less than 60 years, and no previous infarction. Fifty of these patients received intravenous propranolol, and 44 conventional treatment. Eight patients died in hospital or before investigation (three propranolol, five control). Patients with serious unrelated medical disorders were not regarded as suitable for investigation (three propranolol, three control) and one patient in the control group refused investigation. The clinical characteristics of the remaining patients, 44 in the propranolol and 35 in the control group, are listed in Table 1 . Treated patients were older than controls (mean 52 vs 47 years, p = 0 004), but the frequency of previous angina was similar in the two groups. Four patients in the control group and eight in the propranolol group were receiving beta blocker therapy before their infarction. Baseline heart rate and blood pressure before entry to the trial were similar in both groups. The mean time of administration of the first intravenous dose of propranolol was 2-8 hours from the onset of chest pain and was less than 4 hours in all patients. Heart rate fell from a mean of 79 beats per minute to 68 beats per minute within 10 minutes of administration of intravenous propranolol; this resembles the change observed in our previously reported trials in which a reduction of creatine kinase (Table 2) showed that all propranolol subgroups had lower mean end diastolic volumes than the control subgroups, although this (Table 1) . These patients might have been least likely to benefit from intervention, since most of the eventual infarct size was likely to have already been reached. Reanalysis after exclusion of these cases, however, showed no benefit in the propranolol group.
The mean coronary arteriographic score was similar in both groups (propranolol 9 0(2 5), control 8 4 (2-2)). Arteriography showed complete occlusion of the infarct related coronary artery in 76% of patients (propranolol 79%, control 74%). The coronary score of an occluded infarct related artery is a measure of the volume of myocardium distal to the occlusion, and according to our scoring system when it is divided by 15 it estimates the proportion of the left ventricle which has lost its primary blood supply. The mean score of the infarct related coronary artery of the control group was 4 6 (310% of the left ventricle), while that of the propranolol group was also 4 6, indicating that the volume of myocardium at risk from infarction was similar. Comparison of patients treated with propranolol or conventionally in whom incomplete occlusion of the infarct related artery was There was no apparent significant difference in exercise duration or the frequency of angina between propranolol and control groups. End systolic volume, ejection fraction, and subjective assessment of the severity of regional dysfunction were also not significantly different in these groups. There was a trend to lower end diastolic volumes in the propranolol group which approached statistical significance.
The similarity of the groups at entry is clearly important to any conclusions drawn about the value of this intervention. The propranolol group was significantly older with a higher percentage of patients having electrocardiographic ST elevation on entry (p = 0 1) and completed anterior Q wave infarction on discharge (p = NS). The extent of coronary artery disease and the size of the occluded infarct related vascular bed are important determinants of infarct size and these variables were similar in the two groups. There was, however, a wide variance for each index of ventricular function in both groups that was due to spontaneous variation in infarct size. Given the variance in this study, a sample of 107 patients in each group would have been necessary to detect a difference in ejection fraction of 50% at a significance level of 2p = 0-05 with a probability of 80%. No improvement in mean ejection fraction was seen in the propranolol group, however, suggesting that a larger study is unlikely to show a clinically significant improvement in ventricular systolic function.
We believe that ours is the first study to examine adequately the effect on left ventricular function of early intervention with intravenous beta blockers. The effect on ventricular function after infarction of delayed intervention with acebutolol has been reported"1; no significant improvement in late ejection fraction or ventricular volumes was seen when intravenous acebutolol was given six to 24 hours after the onset of chest pain. This protocol, however, was designed to prevent infarct extension rather than to limit infarct size by early intervention. We reported the results of angiocardiography in 28 patients enrolled in an earlier trial of propranolol,°0 but the limited number of patients that we studied may have been responsible for the failure to show improvement in left ventricular function with propranolol.
Experimental and clinical evidence strongly suggests, however, that infarct size is limited after intra-354 300-
250-
Propranolol during acute infarction venous administration of beta blockers. Experimental evidence is based on reduction of the extent of infarction seen at necropsy, [12] [13] [14] preservation of creatine kinase enzyme activity,15 and prevention of microvascular'6 and mitochondrial"7 injury. Creatine kinase release correlates strongly with anatomical infarct size measured at necropsy in patients who die from infarction,18-20 and it also correlates reasonably well with subjective assessment of myocardial function assessed by cineangiography after infarction8 and assessment of the percentage of abnormally contracting segments. 21 We have previously shown a 20%-30% reduction in creatine kinase release when propranolol was given within four hours of the onset of chest pain,210 and this result has been confirmed in further trials that assessed the effect of other beta blockers.34 Important variables such as the maximal duration of chest pain and the propranolol regimen used in this study were identical to those in our previous studies. The reduction in double product after intravenous and oral propranolol was also similar, and, although a measurement of creatine kinase release was not repeated in this study, there is no reason to expect a result dissimilar to our previous studies. Vectorcardiographic analysis also correlates with extent of infarction determined experimentally in baboons,22 and preservation of QRS vector has been reported with timolol. 4 A conclusion from the evidence cited above is that limitation of infarct size by 20%-30% with early administration of beta blockers should lead to improvement in ventricular function. This hypothesis has not previously been tested and is not supported by our results. Experimental evidence, however, suggests that limitation of infarct size by 20%-30% would not necessarily lead to a parallel improvement in myocardial function. Hearse and Yellon have addressed the controversy about the border zone of infarction and have suggested that a significant border zone does not exist at the edge of the developing infarction, but rather lies in the transmural plane between subepicardium and subendocardium.23 Flow gradients in the transmural plane favouring the subepicardium occur after acute coronary artery ligation in dogs5 24 and it is the subepicardium which seems to be protected by treatment with propranolol. 2"5 A similar situation has been reported in man,25 where the relation of infarct size to the vascular bed at risk was the result of variation in the transmural extent of necrosis and not the result of variation in the lateral zone of viable muscle, which was consistently narrow.
Preservation of subepicardial myocardium may not contribute to regional function. Sonomicrometry in normal myocardiumn of dogs has shown that the 355 inner half of the myocardium contributes approximately 70%-80% of the overall wall thickening,2627 so that the subepicardial myocardium may not contribute greatly to total wall thickening. Ellis et al recently reported on the correlation of infarct size with myocardial contractile function in dogs during coronary artery reperfusion.28 Reduction by more than 40% of the transmural extent of infarction was necessary before there was a significant improvement in contractile function. Thus salvage of myocardium in the infarct zone to the degree seen with propranolol may not be sufficient to result in an improvement in ventricular systolic function.
It is conceivable, however, that preservation of subepicardium might splint the infarct zone and prevent infarct expansion.29 This could limit the increase in end diastolic volume, and this would accord with the trend which we found in the present study. None the less the functional sequelae at best appear to be small and we consider it unlikely that beta blocker therapy will significantly reduce mortality from cardiogenic shock or cardiac failure. Improved myocardial preservation may result from the combination of treatment with beta blockers and reperfusion,30 while maintaining the benefit of prevention of ventricular fibrillation.6 
